Advanced search
Publication Cover
Current Medical Research and Opinion Volume 27, 2011 - Issue 9
Submit an article Journal homepage
1,096
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders

C.J. Guico-PabiaPfizer Inc. Collegeville, PA, USACorrespondence[email protected]
,
Q. JiangPfizer Inc. Collegeville, PA, USA
,
P.T. NinanPfizer Inc. Collegeville, PA, USA
&
M.E. ThaseUniversity of Pennsylvania School of Medicine Philadelphia, PA, USA
Pages 1815-1826 | Accepted 11 Jul 2011, Published online: 04 Aug 2011

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Gaia Sampogna, Filippo Caraci, Claudia Carmassi, Bernardo Dell’Osso, Silvia Ferrari, Giovanni Martinotti, Gabriele Sani, Gianluca Serafini, Maria Salvina Signorelli & Andrea Fiorillo. (2023) Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper. Expert Opinion on Pharmacotherapy 24:14, pages 1511-1525.
Read now
Tempei Otsubo, Yoshinori Watanabe, Seiji Hongo, Mikichika Inoue, Kimiko Akimoto, Ken Murakami, Ryutaro Takahashi & Toshiaki Kikuchi. (2018) Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study. Neuropsychiatric Disease and Treatment 14, pages 955-966.
Read now
Chi-Un Pae. (2011) Desvenlafaxine in the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy 12:18, pages 2923-2928.
Read now

Articles from other publishers (2)

Narcís Cardoner Álvarez. (2013) Desvenlafaxina, un nuevo IRSN para el tratamiento de la depresión mayor: Revisión de la literatura. Psiquiatría Biológica 20:1-2, pages 2-7.
Crossref
Thomas L. Schwartz. (2012) Metabolites: novel therapeutics or “me-too” drugs? Using desvenlafaxine as an example. CNS Spectrums 17:3, pages 103-106.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.